Nasdaq · Healthcare
GeneDx Holdings Corp. (WGS)
As-reported financials and recent SEC filings for GeneDx Holdings Corp., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$427.5M
Net income
$-21.0M
Net margin
-4.9%
Diluted EPS
$-0.73
ROE
-6.8%
P/E (TTM)
—
Market cap
$2.07B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $427.5M | $305.4M | $202.6M | $234.7M | $212.2M |
| Gross profit | $298.2M | $194.4M | $90.0M | $-26.8M | $-16.6M |
| Operating income | $-13.1M | $-23.2M | $-180.6M | $-667.7M | $-446.1M |
| Net income | $-21.0M | $-52.3M | $-175.8M | $-549.0M | $-245.4M |
| Diluted EPS | $-0.73 | $-1.94 | $-7.23 | $-26.82 | $-12.48 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →8-K2026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →Go deeper on WGS
Search GeneDx Holdings Corp.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.